Protocol to prepare PARPi-combined LIN28B siRNA nanoparticles and evaluate therapeutic efficacy of malignant ascites

Steps for preparing LIN28B siRNA-loaded nanoparticles • Procedures for establishing a murine malignant ascites model • Instructions for administering nanoparticles and PARP inhibitors in vivo • Methods for assessing tumor burden and vascular permeability Publisher’s note: Undertaking any experimental protocol requires adherence to local institutional guidelines for laboratory safety and ethics. Summary Malignant serous effusion (MSE) is a life-threatening complication of advanced cancers with limited effective treatments. Here, we present a protocol for the preparation of LIN28B siRNA-loaded nanoparticles and their combination with PARP inhibition for therapeutic evaluation in malignant ascites (MA). We describe steps for nanoparticle formulation, establishment of murine ascites models, and in vivo administration of therapeutic agents. We then detail procedures for assessing tumor progression, vascular permeability, and endothelial junction integrity to evaluate treatment efficacy and microenvironmental remodeling. For complete details on the use and execution of this protocol, please refer to Fang et al. 1 Download: Download high-res image (221KB) Download: Download full-size image